2-Oxo-Clopidogrel Composition for Stable Oral Bioequivalence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical formulations of (7aS, 2'S)-2-oxo-clopidogrel face challenges in achieving bioequivalence to clopidogrel due to low solubility, high permeability, and individual variability in metabolism, leading to inconsistent Tmax, Cmax, and AUC, which complicates the treatment and prevention of blood coagulation-related diseases.
Innovation Solution
A pharmaceutical composition comprising (7aS, 2'S)-2-oxo-clopidogrel with a controlled particle size D90 of 3 μm to 8 μm and a therapeutically effective amount of 4 mg to 5.5 mg, combined with specific binders, fillers, disintegrants, and lubricants, ensures a sustained, stable, and complete release, achieving bioequivalence to clopidogrel bisulfate (Plavix®, 75 mg) both before and after meals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct oral administration of compound A is used to avoid clopidogrel resistance, then anticoagulant efficacy is improved, but bioequivalence to clopidogrel cannot be achieved due to poor solubility and high permeability properties
Solution Approach 1:
The patent applies parameter changes by controlling the particle size of compound A to D90: 3-8 μm and adjusting the dosage to 4-5.5 mg, which modifies the drug's absorption characteristics to achieve bioequivalence with clopidogrel while maintaining anticoagulant efficacy
Solution Approach 2:
The patent uses binders, fillers, disintegrants, and lubricants as intermediary substances in the pharmaceutical formulation to facilitate the release and absorption of compound A, enabling consistent bioequivalence to clopidogrel
2Reliability
If compound A with poor solubility is used, then clopidogrel resistance is avoided, but consistent Tmax and bioequivalence of Cmax and AUC become difficult to achieve
Solution Approach 1:
The patent changes the physical parameters of compound A by controlling particle size (D90: 3-8 μm) and dosage (4-5.5 mg), which enables consistent Tmax and bioequivalence of Cmax and AUC while maintaining the advantage of avoiding clopidogrel resistance
Solution Approach 2:
The patent creates a composite pharmaceutical formulation combining compound A with binders, fillers, disintegrants, and lubricants, which facilitates consistent drug release and achieves bioequivalence to clopidogrel
3Stability of the object's composition
If controlled particle size D90 of 3 μm to 8 μm is used, then sustained and stable drug release is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent specifies controlled particle size parameters (D90: 3-8 μm) to achieve sustained and stable drug release, which requires precise manufacturing control but ensures consistent therapeutic effect
Data Source
AI summary
The present invention relates to a composition for treating and resisting blood coagulation and use thereof, and particularly relates to a pharmaceutical composition containing (7aS, 2'S)-2-oxo-clopidogrel and use thereof. The present invention provides a medicinal specification of a solid preparation which, after oral administration before/after meals for use in healthy adults, can be similar to clopidogrel bisulfate tablets that are 12.5 times larger in specification in terms of Cmax, AUC(0-t), and AUC(0-∞) of a metabolically produced compound A and an active metabolite H4, thereby ensuring the effectiveness and safety of usage of medication.